688192.SHG Dizal (Jiangsu) Pharmaceutical Co. Ltd. A

Healthcare Pharmaceuticals Shanghai Stock Exchange
64.10 CNY
Close of Nov 4, 2026
35.73 71.26
Market cap
CNY 29.8B
P/E
8.0x
P/B
24.35x
ROE
-37.2%
Dividend yield
0.11%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 688192.SHG undervalued?

Graham number
Price64.10
Graham value21.85
Premium193.4%

688192.SHG trades 193.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A fundamental analysis

No fundamental analysis for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A yet.

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dizal (Jiangsu) Pharmaceutical Co. Ltd. A

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematolog…

Full company profile